NKTR-214 Cover on Cancer Discovery
In the third part of our mini-series on cytokines, we get down and dirty with another pegylated IL-2 approach, this time from Nektar Therapeutics, including an interview with the PI, Dr Adi Diab from MD Anderson Cancer Centre and CSO, Dr Jonathan Zalevsky.
We’ve certainly had many full ranging discussions and chats with the good gentlemen; here we continue our journey to understand more about the science and underlying biology, as well as key biomarkers of response.
We can also be provocative too and put them on the spot regarding their critics and some of the pointed questions that get bandied about, which certainly makes for interesting reading. Are they justified?
What should we be looking for when analysing the data? You can find out for yourselves in the latest expert interview.
Other pertinent topics are also covered including where they’re headed and future data readouts to expect.
To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.
Continuing our in-depth oncology pathology interview with Dr David Rimm (Yale), we take a look at some of the new data his lab presented in Atlanta, where we are now with TMB as a biomarker, and what the future may hold for cancer immunotherapy biomarkers.
Early morning in Atlanta en route to the GWCC and AACR19
In an engaging discussion, Dr Rimm discussed many of the details behind PD-L1 and TMB in terms of what really matters when thinking about these tests and their practical applications. He also shared his candid thoughts on the lung cancer blood TMB data presented at AACR by Prof Solange Peters.
If you missed the first part of the interview with Dr David Rimm, a leading oncology pathologist at Yale, on the various challenges associated with PD-L1 as a biomarker on tumour and immune cells in triple negative breast cancer than you can catch up and read it here.
The second half of the interview with Dr Rimm focuses on TMB, with some more details on the challenges of reading PD-L1 on immune cells and why that is the case…
To learn more from our latest thought leader interview and get a heads up on our latest oncology coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
Imagine being becalmed on boat in the doldrums patiently waiting for the wind to pick up…
Just as experienced sailers learn to make best use of the available knowledge on sea breezes, tides, tidal winds, catspaws, headsails, heels, genoa etc, so immunologists are experimenting with various modalities.
This enables them to develop a more extensive knowledge base before they can use all the available tools more effectively at their disposal in order to chart a course in each tumour type and setting.
That’s a tremendous amount of information and skills that needs to be gathered before we can even consider racing against competition. So it is with cancer immunotherapy, with all its different approaches that are available to combine or sequence in a multitude of tumour types. We are still largely in the unknown unknown stage of figuring things out.
That said, each cancer conference brings new nuggets and gems that on their own do not appear to offer much, but added together in the broader picture can contribute more than many observers realise.
That was certainly the case with our latest update on IO therapies, as you will see…
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
SITC2017 Poster Halls
National Harbor, MD: It’s time for the first of our Gems from the Poster Halls following the Society for Immunotherapy of Cancer (SITC) annual meeting over the weekend.
It’s time for a look at biomarkers of response and some novel approaches in development. In the past we have covered circulating tumour cells (CTCs), cell free DNA (cfDNA), circulating tumour DNA (ctDNA) and even exosomes.
As Monthy Python would say — now for something really different…
What about a more integrated approach?
Yes, it’s possible and no, I’m not talking about the classical nonogram either.
To learn more insights on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.